Mixing several MRI scans to tell tumor regrowth from treatment effects
Original title: Multiparametric MRI radiomics integrating Arterial Spin Labeling, Quantitative Susceptibility Mapping, and Amide Proton Transfer imaging for differentiating glioma recurrence from post-treatment response.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a look back at past scans in people, not a tool doctors can use yet.
The short version
Doctors tested whether combining MRI scan types can tell regrowth from treatment change.
What was studied. Researchers looked back at records for 274 people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary after surgery. Each person had several kinds of MRI scans. Computer models were built from details in those scans.
What they found. Models built from one scan type each did worse than a model that used all the scans together. A scoring chart made from the data worked about as well as the combined model. Both did better than a model that used only age, tumor size, and a gene test.
What this means, and what it doesn't
What it could mean: Combining scan types may one day help doctors read confusing MRI changes after treatment. That could mean fewer guesses about whether a tumor is growing back.
What it doesn't mean: This does not mean a new test is ready for you. The team looked back at past records, so the models are not proven in daily practice. This is research on reading scans, not a treatment, and it is not a cure. Your doctor cannot order this tool today.
Source: PubMed, September 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.